"A Preemptive Strike Against Cancer" (News: Analysis & Commentary, June 7, 2004)
"A preemptive strike against cancer" (News: Analysis & Commentary, June 7) and the accompanying table referred to Merck & Co.'s (MRK
) Proscar (finasteride) as an anti-baldness drug. Proscar, approved for the treatment of enlarged prostates, was able in a large trial to reduce risk of prostate cancer by 25%. Procepia (also finasteride) is used to treat baldness.
"From Pain Therapeutics, A Better Painkiller?" (Inside Wall Street, June 14, 2004)
"From Pain Therapeutics (PTIE
), a better painkiller?" (Inside Wall Street, June 14) should have said it expects to begin Phase III clinical trials by yearend (not file with the Food & Drug Administration for approval).
Copyright 2004, by The McGraw-Hill Companies Inc. All rights reserved.
Printer-Friendly Version
